ATAI

#2152
AtaiBeckley Inc. Common Stock
4.3300 USD
-0.23%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
4.3300
4.3300
Year Range
3.2700
5.5000
Daily Change
-0.23%
Monthly Change
+28.49%
6 month change
+9.62%
Year Change
+9.62%
Previous Close
4.3400
Open
4.3300
Low
4.3300
High
4.3300
Volume
64
Open full chart

Financials

Overview Statement Statistics
Quarterly Annual
  • Market Capitalization 1.5794 B
  • Employee 99
  • Founded 2018
  • CEO Florian Brand
  • Website www.ataibeckley.com
  • Headquarter Delaware, United States
  • FIGI BBG0107FR3K9
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-1.41
Price to sales ratio
226.59

AtaiBeckley Inc

atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways.

News